Novadaq Technologies Inc.TSX: NDQ

Novadaq receives FDA clearance for SPY labeling changes

· Issued by Novadaq Technologies Inc. via CNW
Announces two additional clinical trials for neurosurgery and dialysis 
patients

TORONTO, May 9 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, announced today
that it has received a 510(k) pre-market clearance from the United States Food
and Drug Administration for a labeling revision for its SPY(R) Intra-operative
Imaging System. This labeling will give cardiac surgeons greater flexibility
for the administration of the imaging agent while enhancing image quality
during coronary artery bypass graft (CABG) procedures.
SPY is the first and only fluorescence guided system that enables cardiac
surgeons to visually assess coronary vasculature and bypass grafts during the
course of a CABG procedure. It also allows surgeons to view, record, replay,
print and archive high-quality image sequences of the coronary arteries and   
by-pass grafts. SPY provides surgeons the ability to identify the
unpredictable need to perform graft revisions during the original surgical
procedure - an opportunity that until now, had never been routinely possible.
The revised labeling for the product allows direct injection of the imaging
agent to the vessels in the region of interest. This gives the surgeon greater
flexibility without posing any additional risk to the patient.
The Company also announced the start of two additional clinical trials in
different therapeutic applications for SPY: cerebral angiography during
neurosurgery and the evaluation of access points for renal failure patients
who are undergoing hemodialysis. Both studies are being conducted in Canada.
"The ability to apply our imaging platform to different therapeutic
areas, with no significant investment in technology, demonstrates the
potential to expand the market opportunity for Novadaq over time," said       
Dr. Arun Menawat, CEO and President, Novadaq Technologies Inc. "This is how
LUNA(TM) was conceived and how we intend to continue to pursue opportunities
to become a leading imaging company in the operating room."

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is aimed at
the diagnosis, evaluation, treatment and on-going management of wet Age-
related Macular Degeneration (AMD) by using the same core imaging technology
that is used in the SPY System. The OPTTX System is currently being evaluated
in clinical trials. Novadaq's product for nerve visualization in prostate
surgery, LUNA is designed to enable surgeons to visualize nerve bundles and
the lymphatic system during the course of urological procedures, including
radical prostatectomy in order to reduce negative outcomes including, but not
limited to, impotency. For more information, please visit the company's
website at www.novadaq.com.

Certain matters discussed in this release could constitute forward-
looking statements that are subject to risks and uncertainties relating to
Novadaq's future financial or business performance. Actual results could
differ materially from those anticipated in these forward-looking statements.
Forward-looking information may relate to management's future outlook and
anticipated events or results, and may include statements or information
regarding the future financial position, business strategy and strategic
goals, research and development activities, projected costs and capital
expenditures, financial results, research and clinical testing outcomes, taxes
and plans and objectives of or involving Novadaq. Particularly, information
regarding future sales and marketing activities, future revenues and research
and development activities, as well as the Company's plans for each of the SPY
System, OPTTX System and LUNA System, is forward-looking information.
Forward-looking information is based on certain factors and assumptions
regarding, among other things, market acceptance and the rate of market
penetration of Novadaq's SPY System, the clinical results of the use of the
SPY System, the results from clinical tests of the OPTTX System, and potential
opportunities in the AMD treatment market and in image guided conventional and
minimally invasive urological applications including nerve-sparing radical
prostatectomy. While the Company considers these assumptions to be reasonable
based on information currently available to it, they may prove to be
incorrect.
Forward looking-information is subject to certain factors, including
risks and uncertainties that could cause actual results to differ materially
from what we currently expect. These factors include risks relating to the
transition from research and development activities to commercial activities,
market acceptance and adoption of the SPY System, dependence on key suppliers
for components of the SPY System and the OPTTX System, regulatory and clinical
risks, risks relating to the protection of intellectual property, risks
inherent in the conduct of research and development activities, including the
risk of unfavorable or inconclusive clinical trial outcomes, potential product
liability, competition and the risks posed by potential technological
advances, and risks relating to fluctuations in the exchange rate between the
US dollar and the Canadian dollar.
You should not place undue importance on forward-looking information and
should not rely upon this information as of any other date. While Novadaq may
elect to, Novadaq is under no obligation and does not undertake to update this
information at any particular time.

%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases